首个治疗疼痛和发热的静脉注射产品布洛芬静脉注射液  

The first intravenous ibuprofen product for the treatment of pain and fever

作　　者：李健和[1] 胡焰[2] 谢双[2] 万小敏[1] 易利丹[1] 左运叶[3] 彭六保[1] 

机构地区：[1]中南大学湘雅二医院药学部,长沙410011 [2]中南大学药学院,长沙410013 [3]桂林医学院2012届实习生,桂林541000

出　　处：《中国新药杂志》2012年第14期1573-1577,1582,共6页Chinese Journal of New Drugs

摘　　要：在Medline,EMBASE/EMI,PA及CNKI等数据库中对2011年8月之前有关布洛芬静脉注射液的相关文献进行搜索,并结合生产企业提供的资料以及会议摘要等综述了美国首个批准用于治疗发热和术后疼痛的布洛芬静脉注射液的药理学、药代动力学、临床评价、安全性和耐受性等。临床研究结果表明,布洛芬静脉注射液在治疗轻度至中度疼痛,以及作为阿片类镇痛药的辅助药物治疗中度至重度疼痛以及解热方面有良好疗效,且不良反应少。其长期临床疗效、急性疼痛治疗以及特殊人群使用等方面还有待进一步研究。This paper reviews the current data on the first intravenous inbuprofen product approved in the United States for the management of post-operative pain and fever, including the pharmacology, pharmacokinetics, clinical evaluation, safety and tolerability and so on. Articles involving the terms of intravenous inbuprofen and cited references published before the end of August 2011 were searched in Medline, EMBASE/EM, IPA, CNKI, and other electronic databases. The information provided by the manufacturers and meeting abstract were also in- cluded. More and more clinical studies demonstrated that intravenous ibuprofen has good effect in the management of mild to moderate pain as a single therapy or moderate to severe pain as an adjunct to opioid analgesics as well as fever. It has few side effects. But further data on intravenous ibuprofen are needed to define its long-term efficacy, efficacy for acute pain, and use in special populations.

关 键 词：布洛芬 静脉注射液 药理学 药代动力学 临床评价 安全性 耐受性 

分 类 号：R971.1[医药卫生—药品]